Equities analysts expect that Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) will post sales of $11.52 million for the current quarter, according to Zacks. Five analysts have issued estimates for Agios Pharmaceuticals’ earnings. The highest sales estimate is $12.50 million and the lowest is $9.90 million. Agios Pharmaceuticals posted sales of $6.98 million in the same quarter last year, which would indicate a positive year over year growth rate of 65%. The firm is expected to report its next earnings report before the market opens on Tuesday, August 8th.

According to Zacks, analysts expect that Agios Pharmaceuticals will report full year sales of $11.52 million for the current year, with estimates ranging from $42.90 million to $58.53 million. For the next fiscal year, analysts anticipate that the firm will post sales of $126.48 million per share, with estimates ranging from $70.40 million to $232.90 million. Zacks’ sales averages are an average based on a survey of analysts that cover Agios Pharmaceuticals.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.80) by $0.24. The firm had revenue of $10.51 million during the quarter, compared to analysts’ expectations of $9.65 million. Agios Pharmaceuticals had a negative net margin of 491.54% and a negative return on equity of 71.20%. The company’s revenue was down 66.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.64) earnings per share.

Several equities research analysts have recently commented on the company. Oppenheimer Holdings, Inc. set a $75.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, June 11th. Credit Suisse Group reissued an “outperform” rating and issued a $61.00 price objective on shares of Agios Pharmaceuticals in a report on Tuesday, April 18th. Zacks Investment Research raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, April 28th. Janney Montgomery Scott reissued a “hold” rating on shares of Agios Pharmaceuticals in a report on Tuesday, August 1st. Finally, Canaccord Genuity set a $90.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 2nd. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $67.25.

Shares of Agios Pharmaceuticals (AGIO) opened at 61.46 on Monday. The firm has a 50-day moving average of $55.14 and a 200-day moving average of $50.99. The firm’s market capitalization is $2.96 billion. Agios Pharmaceuticals has a 1-year low of $35.84 and a 1-year high of $67.74.

In other Agios Pharmaceuticals news, CEO David P. Schenkein sold 3,000 shares of the firm’s stock in a transaction on Wednesday, June 7th. The stock was sold at an average price of $50.02, for a total transaction of $150,060.00. Following the completion of the sale, the chief executive officer now owns 1,100 shares of the company’s stock, valued at approximately $55,022. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lewis Clayton Jr. Cantley sold 2,036 shares of the firm’s stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $47.10, for a total value of $95,895.60. Following the sale, the director now directly owns 91,206 shares of the company’s stock, valued at approximately $4,295,802.60. The disclosure for this sale can be found here. Insiders have sold a total of 79,120 shares of company stock valued at $4,557,207 in the last ninety days. Insiders own 10.55% of the company’s stock.

Large investors have recently made changes to their positions in the stock. FMR LLC increased its stake in shares of Agios Pharmaceuticals by 0.5% in the first quarter. FMR LLC now owns 6,331,747 shares of the biopharmaceutical company’s stock valued at $369,774,000 after buying an additional 32,931 shares in the last quarter. BB Biotech AG increased its stake in shares of Agios Pharmaceuticals by 1.1% in the first quarter. BB Biotech AG now owns 2,839,528 shares of the biopharmaceutical company’s stock valued at $165,828,000 after buying an additional 30,000 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Agios Pharmaceuticals by 5.2% in the first quarter. Vanguard Group Inc. now owns 2,597,391 shares of the biopharmaceutical company’s stock valued at $151,688,000 after buying an additional 129,159 shares in the last quarter. BlackRock Inc. increased its stake in Agios Pharmaceuticals by 8,463.5% in the first quarter. BlackRock Inc. now owns 2,167,074 shares of the biopharmaceutical company’s stock worth $126,556,000 after buying an additional 2,141,768 shares in the last quarter. Finally, First Trust Advisors LP increased its stake in Agios Pharmaceuticals by 52.3% in the second quarter. First Trust Advisors LP now owns 973,870 shares of the biopharmaceutical company’s stock worth $50,106,000 after buying an additional 334,291 shares in the last quarter. 84.53% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Brokerages Expect Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Will Post Quarterly Sales of $11.52 Million” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/07/brokerages-expect-agios-pharmaceuticals-inc-nasdaqagio-will-post-quarterly-sales-of-11-52-million.html.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Get a free copy of the Zacks research report on Agios Pharmaceuticals (AGIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.